Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Breaking Down the First “Breakthrough”

This article was originally published in RPM Report

Executive Summary

Vertex’ cystic fibrosis research is the recipient of the first two “Breakthrough” designations issued by FDA. That underscores the likelihood that the primary value of the new pathway will be as a badge for investors. And that’s probably a good thing.


Related Content

FDA’s “Breakthrough” Exceeds Expectations; Will It Break The Bank?
Personalized Medicine’s Coming of Age Story
PDUFA V and Investor Communications
PDUFA V and Investor Communications
FDA’s First Breakthrough Designations Continue Vertex Kalydeco’s Regulatory Successes
With Final Data Unveiled, Vertex Will Move Its CF Combo Into Pivotal Trials In 2013
“Breakthrough Therapy”: New Pathway in FDASIA May Point The Way To Future Reforms
Innovative Drug Development: Kalydeco Provides A Paradigm, FDA’s Spielberg Says
Vertex Gets Quick FDA Approval Of Kalydeco; Prices New CF Drug At $294,000 Per Year
Expedited Approval Pathway Concept Draws Strong Support But Different Proposals


Related Companies




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts